Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).